Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3409]

Moving precision medicine for lung cancer into the adjuvant setting

Dr Don Gibbons - The University of Texas MD Anderson Cancer Center, Houston, USA

Moving precision medicine for lung cancer into the adjuvant setting ( Dr Don Gibbons - The University of Texas MD Anderson Cancer Center, Houston, USA )

WIN Symposium 2015 highlights

Prof Richard Schilsky - Chief Medical Officer of the American Society of...

WIN Symposium 2015 highlights ( Prof Richard Schilsky - Chief Medical Officer of the American Society of Oncology (ASCO) )

Next generation of trials with targeted agents

Prof Richard Schilsky - Chief Medical Officer of the American Society of...

Next generation of trials with targeted agents ( Prof Richard Schilsky - Chief Medical Officer of the American Society of Oncology (ASCO) )

Ibrutinib combined with bendamustine plus rituximab in previously treated CLL...

Dr Paula Cramer - University of Cologne, Köln, Germany

Ibrutinib combined with bendamustine plus rituximab in previously treated CLL and SLL ( Dr Paula Cramer - University of Cologne, Köln, Germany )

Chemoresistance and residual disease promoted by DNMT3A R882 in AML

Dr Olga Guryanova - Memorial Sloan Kettering Cancer Center, New York, USA

Chemoresistance and residual disease promoted by DNMT3A R882 in AML ( Dr Olga Guryanova - Memorial Sloan Kettering Cancer Center, New York, USA )

TAT 2016: Targeted anticancer therapies

Dr Giuseppe Giaccone - Georgetown University Medical Center, Washington, USA

TAT 2016: Targeted anticancer therapies ( Dr Giuseppe Giaccone - Georgetown University Medical Center, Washington, USA )

Comment: Venetoclax with rituxumab highly active in relapsed refractory CLL

Prof Anton Hagenbeek - University Medical Center Utrecht, Utrecht, Netherlands

$Comment: Venetoclax with rituxumab highly active in relapsed refractory CLL ( Prof Anton Hagenbeek - University Medical Center Utrecht, Utrecht, Netherlands )$

EHA 2015 highlights

Peter Goodwin - ecancer reporter

EHA 2015 highlights ( Peter Goodwin - ecancer reporter )

PDL1 expression in thymic tumours

Dr Giuseppe Giaccone - Georgetown University Medical Center, Washington, USA

PDL1 expression in thymic tumours ( Dr Giuseppe Giaccone - Georgetown University Medical Center, Washington, USA )

Exciting update on the Repurposing Drugs in Oncology (ReDO) project

Dr Gauthier Bouche - Anticancer Fund, Strombeek-Bever, Belgium

Exciting update on the Repurposing Drugs in Oncology (ReDO) project ( Dr Gauthier Bouche - Anticancer Fund, Strombeek-Bever, Belgium )

EHA 2015: Reviewing the treatment landscapes of CLL, MCL, and MM

Prof John Gribben, Prof Marivi Mateos, Prof Umberto Vitolo, Prof Paolo Ghia

EHA 2015: Reviewing the treatment landscapes of CLL, MCL, and MM ( Prof John Gribben, Prof Marivi Mateos, Prof Umberto Vitolo, Prof Paolo Ghia )

Overview of innovation in Hodgkin's lymphoma

Prof Volker Diehl - Winner of the Jean Bernard Lifetime Achievement Award

Overview of innovation in Hodgkin's lymphoma ( Prof Volker Diehl - Winner of the Jean Bernard Lifetime Achievement Award )

More from ecancer